During 2019, EpiTech concluded its First in Human Trial, treating a total of 29 subjects with moderate to severe dry eye disease.
Trial results were excellent, showcasing a response rate that is far above current industry standards with clinically significant improvement in both signs and symptoms, as well as a reduction in eye lubricant use.